BOEING CO/THE (BA)

US0970231058 - Common Stock

170.986  -0.88 (-0.51%)

Fundamental Rating

1

BA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 65 industry peers in the Aerospace & Defense industry. BA has a bad profitability rating. Also its financial health evaluation is rather negative. BA does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

BA had negative earnings in the past year.
BA had a negative operating cash flow in the past year.
In the past 5 years BA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: BA reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -5.79%, BA is doing worse than 70.31% of the companies in the same industry.
Industry RankSector Rank
ROA -5.79%
ROE N/A
ROIC N/A
ROA(3y)-2.75%
ROA(5y)-3.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BA's Gross Margin of 3.13% is on the low side compared to the rest of the industry. BA is outperformed by 84.38% of its industry peers.
In the last couple of years the Gross Margin of BA has declined.
The Profit Margin and Operating Margin are not available for BA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-12.55%

1

2. Health

2.1 Basic Checks

BA does not have a ROIC to compare to the WACC, probably because it is not profitable.
BA has more shares outstanding than it did 1 year ago.
BA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BA has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.15, we must say that BA is in the distress zone and has some risk of bankruptcy.
BA has a worse Altman-Z score (1.15) than 79.69% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.15
ROIC/WACCN/A
WACC8.96%

2.3 Liquidity

BA has a Current Ratio of 1.12. This is a normal value and indicates that BA is financially healthy and should not expect problems in meeting its short term obligations.
BA's Current ratio of 1.12 is on the low side compared to the rest of the industry. BA is outperformed by 78.13% of its industry peers.
BA has a Quick Ratio of 1.12. This is a bad value and indicates that BA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.27, BA is not doing good in the industry: 96.88% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.27

3

3. Growth

3.1 Past

BA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -110.42%.
Looking at the last year, BA shows a decrease in Revenue. The Revenue has decreased by -3.25% in the last year.
Measured over the past years, BA shows a decrease in Revenue. The Revenue has been decreasing by -5.11% on average per year.
EPS 1Y (TTM)-110.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220.25%
Revenue 1Y (TTM)-3.25%
Revenue growth 3Y9.87%
Revenue growth 5Y-5.11%
Sales Q2Q%-1.46%

3.2 Future

The Earnings Per Share is expected to grow by 28.89% on average over the next years. This is a very strong growth
BA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.26% yearly.
EPS Next Y-185.82%
EPS Next 2Y42.73%
EPS Next 3Y41.3%
EPS Next 5Y28.89%
Revenue Next Year-11.03%
Revenue Next 2Y5.6%
Revenue Next 3Y8.75%
Revenue Next 5Y9.26%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

BA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 788.85 indicates a quite expensive valuation of BA.
Based on the Price/Forward Earnings ratio, BA is valued a bit more expensive than 65.63% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BA to the average of the S&P500 Index (23.45), we can say BA is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 788.85

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BA's earnings are expected to grow with 41.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.73%
EPS Next 3Y41.3%

0

5. Dividend

5.1 Amount

BA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BOEING CO/THE

NYSE:BA (1/3/2025, 2:15:05 PM)

170.986

-0.88 (-0.51%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)10-23 2024-10-23/bmo
Earnings (Next)01-29 2025-01-29/amc
Inst Owners67.55%
Inst Owner Change-1.24%
Ins Owners0.07%
Ins Owner Change1.74%
Market Cap127.76B
Analysts75.26
Price Target187.73 (9.79%)
Short Float %3.07%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)-11.02%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.57%
Min EPS beat(2)-42.81%
Max EPS beat(2)3.66%
EPS beat(4)3
Avg EPS beat(4)10.04%
Min EPS beat(4)-42.81%
Max EPS beat(4)41.54%
EPS beat(8)4
Avg EPS beat(8)-91.28%
EPS beat(12)4
Avg EPS beat(12)-1004.62%
EPS beat(16)5
Avg EPS beat(16)-766.07%
Revenue beat(2)0
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-4.97%
Max Revenue beat(2)-2.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-4.97%
Max Revenue beat(4)1.29%
Revenue beat(8)2
Avg Revenue beat(8)-1.45%
Revenue beat(12)2
Avg Revenue beat(12)-5.07%
Revenue beat(16)3
Avg Revenue beat(16)-4.37%
PT rev (1m)0.27%
PT rev (3m)-13.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-355.67%
EPS NY rev (1m)-0.45%
EPS NY rev (3m)-288.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.01%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-8.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 788.85
P/S 1.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.94
EYN/A
EPS(NY)0.22
Fwd EY0.13%
FCF(TTM)-9.84
FCFYN/A
OCF(TTM)-7.03
OCFYN/A
SpS98.09
BVpS-31.52
TBVpS-45.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.79%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.13%
FCFM N/A
ROA(3y)-2.75%
ROA(5y)-3.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-12.55%
F-Score1
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 116.21%
Cap/Sales 2.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.27
Altman-Z 1.15
F-Score1
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)63.17%
Cap/Depr(5y)66.77%
Cap/Sales(3y)1.79%
Cap/Sales(5y)1.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-110.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220.25%
EPS Next Y-185.82%
EPS Next 2Y42.73%
EPS Next 3Y41.3%
EPS Next 5Y28.89%
Revenue 1Y (TTM)-3.25%
Revenue growth 3Y9.87%
Revenue growth 5Y-5.11%
Sales Q2Q%-1.46%
Revenue Next Year-11.03%
Revenue Next 2Y5.6%
Revenue Next 3Y8.75%
Revenue Next 5Y9.26%
EBIT growth 1Y-359.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-523.3%
EBIT Next 3Y134.7%
EBIT Next 5Y83.65%
FCF growth 1Y-2018.16%
FCF growth 3YN/A
FCF growth 5Y-20%
OCF growth 1Y-780.8%
OCF growth 3YN/A
OCF growth 5Y-17.21%